eFFECTOR Therapeutics, Inc.
EFTR · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 148.5% | -96.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 98.5% | 98.3% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -912% | -2,330.6% | 37.7% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | $0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | – | -363.8% | 1,104.8% | 33.8% |
| EPS | -16.37 | -7.85 | 9.78 | 0.28 |
| % Growth | -108.5% | -180.3% | 3,392.9% | – |
| EPS Diluted | -16.37 | -7.85 | 9.78 | 0.1 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | – | -573.1% | 1,229.8% | 38.2% |